Literature DB >> 21508937

Environmental and genetic factors affecting transport of imatinib by OATP1A2.

K Eechoute1, R M Franke, W J Loos, L A Scherkenbach, I Boere, J Verweij, H Gurney, R B Kim, R G Tirona, R H J Mathijssen, A Sparreboom.   

Abstract

The bioavailability of orally administered imatinib is >90%, although the drug is monocationic under the acidic conditions in the duodenum. In vitro, we found that imatinib is transported by the intestinal uptake carrier organic anion transporting polypeptide (OATP1A2) and that this process is sensitive to pH, rosuvastatin, and genetic variants. However, in a study in patients with cancer, imatinib absorption was not associated with OATP1A2 variants and was unaffected by rosuvastatin. These findings highlight the importance of verifying in a clinical setting the drug-transporter interactions observed in in vitro tests.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508937      PMCID: PMC3476732          DOI: 10.1038/clpt.2011.42

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Acid-base profiling of imatinib (gleevec) and its fragments.

Authors:  Zoltán Szakács; Szabolcs Béni; Zoltán Varga; László Orfi; György Kéri; Béla Noszál
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

2.  ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.

Authors:  Liyue Huang; Yi Wang; Scott Grimm
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

Review 3.  Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.

Authors:  Michael Schachter
Journal:  Fundam Clin Pharmacol       Date:  2005-02       Impact factor: 2.748

4.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Authors:  F McTaggart; L Buckett; R Davidson; G Holdgate; A McCormick; D Schneck; G Smith; M Warwick
Journal:  Am J Cardiol       Date:  2001-03-08       Impact factor: 2.778

Review 5.  Drug transporters and imatinib treatment: implications for clinical practice.

Authors:  Karel Eechoute; Alex Sparreboom; Herman Burger; Ryan M Franke; Gaia Schiavon; Jaap Verweij; Walter J Loos; Erik A C Wiemer; Ron H J Mathijssen
Journal:  Clin Cancer Res       Date:  2010-12-16       Impact factor: 12.531

6.  Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.

Authors:  Ian Judson; Peiming Ma; Bin Peng; Jaap Verweij; Amy Racine; Eugenio Donato di Paola; Martine van Glabbeke; Sasa Dimitrijevic; Michelle Scurr; Herlinde Dumez; Allan van Oosterom
Journal:  Cancer Chemother Pharmacol       Date:  2004-12-09       Impact factor: 3.333

7.  Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.

Authors:  Wooin Lee; Hartmut Glaeser; L Harris Smith; Richard L Roberts; Gilbert W Moeckel; Guillermo Gervasini; Brenda F Leake; Richard B Kim
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

8.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Authors:  Herman Burger; Hans van Tol; Antonius W M Boersma; Mariël Brok; Erik A C Wiemer; Gerrit Stoter; Kees Nooter
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

9.  Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.

Authors:  Bin Peng; Catherine Dutreix; Gunther Mehring; Michael J Hayes; Monique Ben-Am; Michael Seiberling; Rolf Pokorny; Renaud Capdeville; Peter Lloyd
Journal:  J Clin Pharmacol       Date:  2004-02       Impact factor: 3.126

10.  Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.

Authors:  Paul D Martin; Mike J Warwick; Aaron L Dane; Steve J Hill; Petrina B Giles; Paul J Phillips; Eva Lenz
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

View more
  16 in total

1.  The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.

Authors:  A C C Costa; E B Coelho; V L Lanchote; B V Correia; J T Abumansur; G R Lauretti; N V de Moraes
Journal:  Eur J Clin Pharmacol       Date:  2017-04-14       Impact factor: 2.953

2.  SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma.

Authors:  Viktor Hlavac; Radka Vaclavikova; Veronika Brynychova; Pavel Dvorak; Katerina Elsnerova; Renata Kozevnikovova; Karel Raus; Katerina Kopeckova; Sona Mestakova; David Vrana; Jiri Gatek; Pavel Soucek
Journal:  Mol Diagn Ther       Date:  2021-01-02       Impact factor: 4.074

3.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

Review 4.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors:  K Mandery; H Glaeser; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.

Authors:  Jing Li; Jianmei Wu; Xun Bao; Norissa Honea; Youming Xie; Seongho Kim; Alex Sparreboom; Nader Sanai
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

6.  Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.

Authors:  Hannah H Lee; Brenda F Leake; Richard B Kim; Richard H Ho
Journal:  Mol Pharmacol       Date:  2016-10-24       Impact factor: 4.436

Review 7.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

Review 8.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

9.  Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2.

Authors:  Fanfan Zhou; Jian Zheng; Ling Zhu; Andreas Jodal; Pei H Cui; Mark Wong; Howard Gurney; W Bret Church; Michael Murray
Journal:  AAPS J       Date:  2013-08-06       Impact factor: 4.009

Review 10.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.